Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Rhea-AI Summary
Matinas BioPharma (NYSE American: MTNB) received a notice on June 24, 2026 that it is not in compliance with NYSE American listing standards requiring minimum stockholders’ equity of $4.0 million and $6.0 million under Sections 1003(a)(ii) and 1003(a)(iii).
The company reported equity of $3.02 million as of March 31, 2026 and $4.83 million as of December 31, 2025, with losses in its five most recent fiscal years. NYSE American accepted Matinas BioPharma’s compliance plan and granted a plan period through October 2, 2027, during which the stock will continue trading, subject to quarterly monitoring and potential delisting if progress is insufficient.
Positive
- NYSE American accepted a compliance plan with a deadline of October 2, 2027
- Shares continue to be listed and traded on NYSE American during the plan period
- Notice does not affect ongoing business operations or SEC reporting requirements
Negative
- Stockholders’ equity $3.02 million vs. $4.0 million requirement under Section 1003(a)(ii)
- Stockholders’ equity $4.83 million vs. $6.0 million requirement under Section 1003(a)(iii)
- Company has reported losses in its five most recent fiscal years
- Risk of NYSE American delisting if compliance not achieved or plan milestones missed
News Market Reaction – MTNB
In the Jun 29 session, MTNB gained 3.36%, reflecting a moderate positive market reaction. Argus tracked a trough of -17.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 03 | Listing compliance notice | Negative | +0.6% | First NYSE American notice for failing equity standards after multi-year losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history shows a prior NYSE American non-compliance notice drew a small positive reaction despite negative implications.
Key Terms
stockholders’ equity financial
continued listing standards regulatory
plan period regulatory
delisting proceedings regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least
On May 4, 2026, the Company submitted a plan (the “Plan”) to the NYSE American advising of actions it has taken or will take to regain compliance with the continued listing standards. The Notice indicated that the NYSE American staff had determined to accept the Plan and grant the Company a plan period through October 2, 2027 (the “Plan Period,” and such date, the “Plan Period Deadline”). Accordingly, the Company is able to continue its listing during the Plan Period and will be subject to periodic reviews, including quarterly monitoring, for compliance with the Plan until it has regained compliance. However, there can be no assurance that the Company will be able to achieve compliance with such standards within the Plan Period. If the Company is not in compliance with the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the Plan during the Plan Period, then NYSE American staff may initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.
The Notice has no immediate impact on the listing of the Company’s shares of common stock, which will continue to be listed and traded on the NYSE American, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
About MAT2203
Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.
For more information, please visit www.matinasbiopharma.com.
Forward-Looking Statements
This release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this release are forward-looking statements. Forward-looking statements contained in this release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including with respect to the Company’s plans related to regaining compliance with the NYSE American’s continued listing standards. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the risk disclosures in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025 and in other filings made with the Securities and Exchange Commission by the Company. All such forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Investor Contact Jerome D. Jabbour Chief Executive Officer (908) 484-8805 operations@matinasbiopharma.com